Australia's biotech industry sings Korea's praises, asks for more tie-ups

There was a lot of back slapping at this year's Australian Clinical Trial Seminar, held last week, that aimed to showcase Australia's capabilities and strengths in the clinical trial industry. The events, part of a collaboration project between the Korea Health Industry Development Institute and trade group AusBiotech, saw AusBiotech's COO Glenn Cross tell the Korea Times: "(South) Korea is one of AusBiotech's priority countries in the Asian region. I would like to see increased collaboration between Korean and Australian companies, especially in the regenerative medicine area through this visit." He added: "Australia welcomes more investment from Korean venture capital into Australia and active research and development and marketing activities by Korean companies." This comes just a week after Korean biotech startups were given a new boost after the government announced they would be helped with extra funding and advice. Report

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

To show Brukinsa is better than AbbVie and J&J's blockbuster Imbruvica, BeiGene is running phase 3 head-to-head trials in blood cancers.